Anti-TNF-alpha in 2002: Adverse events, new indications other than rheumatoid arthritis and spondylarthropathies;Inhibiteurs du TNF-alpha en 2002: Effets indésirables, surveillance, nouvelles indications en dehors de la polyarthrite rhumatoïde et des spondylarthropathies

Revue du Rhumatisme (Edition Francaise)

Volumn 69, Issue 10-11, 2002, Pages 982-991

  Mariette, Xavier ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Adverse event; Anti TNF; Education; Immunotherapy; Systemic disease

Indexed keywords

EID: 1542457485     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(02)00427-1     Document Type: Short Survey

References (32)

1. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KF, Fleischmann RM, Fox IR, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor : Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:256-9.
2. Lipsky P, Van Der Heijde D, St Clair W, Durst D, Breedveld F, Kalden J, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease : the ACCENT I randomised trial. The Lancet 2002;359:1541-9.
4. Keane J, Gershon S, Pharm D, Wise RP, MD, MPH, et al. Tuberculosis associated with Infliximab, a tumor necrosis factor α - neutralizing agent. N England J Med 2001;345:1098-2104.
5. Wallis WJ, Burge DJ, Holman J, Spencer-Green G, Gardiner M. Infection reports with etanercept (Enbrel®) therapy. Arthritis & Rheumatism 2001;44:154.
6. Abitbol V, Berenbaum F, Breban M, Bricaire F, Colombel JF, Dautzenberg B, et al. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002;69:170-2.
7. Keenan GF, Clark J, Baker DG, Jones S. The rare occurrence of fungal infections in patients receiving infliximab. Arthritis & Rheumatism 2001;44:180.
8. Peterson CJR, Wener MH, Hsu FC, Simkin PA. Safety of TNF-& antagonists in patients with rheumatoid arthritis and chrom hepatitis. Arthritis & Rheumatism 2001;44:156.
9. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, Veys EM. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropaty. Arthritis Rheum 2002;46:755-65.
10. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. The Lancet 2002;359:579-80.
11. Demyelination occurring during anti-TNF-α therapy. Neurology 1999;53:457-65.
12. Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. The Lancet 2001;358:1784.
13. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis &. Rheumatism 2001;44:2862-9.
14. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Longterm Safety and efficacy of etanercept in Patients with Rheumatoid Arthritis. The Journal of Rheumatology 2001;28:1238-44.
15. Mariette X, Cazals-Hatem D, Liote F, Warszawski J, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate. A three year prospective study in France. Blood 2002;99:3909-15.
16. Koski H, Janin A, Humphreys-Beher MG, Sorsa T, Malmström M, Konttinen YT. Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjögren's syndrome. Clin Exp Rheumatol 2000;19:131-7.
17. Matsumura R, Umemiya K, Goto T, Nakazawa T, Ochiai K, Kagami M, et al. Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol 2000;18:311-8.
18. Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Harada K, et al. Suppression of tumor necrosis factor induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear fact B complementary DNA into immortalized human salivary gland acinar cells. Arthritis Rheum 2000;43:1756-67.
19. Soliven B, Wang N. Tumor necrosis factor-alpha regulates nicotinic responses in mixed cultures of sympathetic neurones and nondueronal cells. J Neurochem 1995;64:883-94.
20. Tornwall J, Fox H, Edwards C, Fox R. Treatment with pegylated recombinant methionyl human soluble tumor necrosis factor-type 1 receptor (PEG-s TNF R1) prevents development of Sjögren's syndrome and diabetes in the NOD mouse model. Arthritis Rheum 1999;4(Suppl):403 [abstract].
21. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome : a pilot study. Arthritis Rheum 2001;44:2371-5.
22. Mariette X. Lymphomas complicating Sjögren's syndroma and hepatitis C virus infection could share a common pathogenesis : chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 2001;60:1007-10.
23. Bartolucci P, Ramanoelina J, Cohen P, Le Hello C, Guillevin L. Pilot study on Infliximab for 10 patients with systemic vasculitis not responding to steroids an immunosuppressants. Arthritis & Rheumatism 2001;44:23.
24. Lamprecht P, Vosmink J, Lilienthal T, Bemhard N, Heller M, Gross WL, et al. Successful treatment of refractory wegener's granulomatosis with infliximab. Arthritis & Rheumatism 2001;44:24.
25. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I, Carlo OS. Treatment of longstanding active giant cell arteritis with infliximab : report of four cases. Revue? date;vol?:2933-5.
26. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis. Arthritis &. Rheumatism 2001;44:1149-54.
27. Stikakis PP, Theodossiadis PG, Katsiari CG, Katlamanis P, Markomichelakis NN. Effect of Infliximab on sight-threatening panuveitis in behcet's disease. Lancet 2001;358:295-6.
28. Smith JR, Levinson RD, Holland GN, et al. A differential efficacy of the TNF inhibition in the treatment of inflammatory eye disease and associated rheumatological disease. Arthritis Rheum 2000;43.
29. Cavagna L, Caporali R, Eprs O, Bobbio Pallavivini F, Montecucco C. Infliximab in the treatment of adult still's disease refractory to conventional therapy. Clin Exp Rheumatol 2001;19:329-32.
30. Weinblatt ME, Maier AL, Overman SS, Mease PJ, Fraser PA. Etanercept in Still's disease in the adult. Arthritis Rheum 2000;43.
31. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through NF-κB, and by 17β-estradiol through S in human vascular endothelial cells. J Biol Chem 2000;275:25781-90.
32. Drewe E, Mc Dermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with TRAPS. N Engl J Med 2000;343:1044-5.